Literature DB >> 3487307

Immunologic parameters in patients with thyroid cancer.

K Makimoto, M Ohmura, T Hoshino.   

Abstract

We evaluated various immunologic parameters in patients with papillary and follicular carcinomas of the thyroid gland. Our studies included examinations of peripheral blood lymphocytes and skin reactions to selected antigens. Preoperative peripheral blood tests were found to be normal except for an elevated percentage of IgG X Fc+ T-cells (T gamma). Skin reactions (phytohemagglutinin, purified protein derivative) were greater preoperatively than postoperatively. In postoperative cases without tumor recurrence, absolute numbers of T-cells and lymphocytes were reduced. OK-432 is a biologic response modifier of a streptococcal preparation and was used as immunotherapy in postoperative patients. This therapy seemed to augment the absolute numbers of T-cells and lymphocytes as well as purified protein derivative skin reactions in the patients without tumor recurrences. In the patients with postoperative tumor recurrences, there was an abnormal reduction in the percentage of T-cells and in the absolute numbers of T-cells and lymphocytes. OK-432 treatment was not significantly effective in normalizing this reduction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487307     DOI: 10.1007/BF00453756

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  13 in total

1.  Cellular immunity in patients with epidermoid cancer of the head and neck.

Authors:  P R Papenhausen; A Kukwa; C B Croft; B Borowiecki; C Silver; E E Emeson
Journal:  Laryngoscope       Date:  1979-04       Impact factor: 3.325

2.  T-cell deficiency in patients with squamous cell cancer of the head and neck.

Authors:  H J Wanebo; M Y Jun; E W Strong; H Oettgen
Journal:  Am J Surg       Date:  1975-10       Impact factor: 2.565

3.  [Studies on the determination of IgG-Fc receptor bearing cells and T gamma-cells of human lymphocytes--with a special reference to the comparison of EA rosette method and double rosette methods (author's transl)].

Authors:  S Iho; C Kojima; S Nishimoto; H Furukawa; T Takahashi; T Hoshino
Journal:  Rinsho Byori       Date:  1980

4.  T-cell rosette test in squamous cell carcinoma of the head and neck.

Authors:  R J Eastham; J M Mason; B R Jennings; P W Belew; T A Maguda
Journal:  Arch Otolaryngol       Date:  1976-03

5.  Immunochemotherapy in human lung cancer using the streptococcal agent OK-432.

Authors:  I Kimura; T Ohnoshi; S Yasuhara; M Sugiyama; Y Urabe
Journal:  Cancer       Date:  1976-05       Impact factor: 6.860

6.  Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma.

Authors:  S Kagawa; K Ogura; K Kurokawa; K Uyama
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

7.  Spontaneous rosette formation and rosette inhibition assays in patients with squamous cell carcinoma of the head and neck.

Authors:  M J Deegan; S W Coulthard
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

8.  Observations on immunologic parameters in laryngeal cancer patients.

Authors:  K Makimoto; A Tamada; S Kishimoto; N Kanoh; T Hoshino
Journal:  Arch Otorhinolaryngol       Date:  1983

9.  Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.

Authors:  L Moretta; S R Webb; C E Grossi; P M Lydyard; M D Cooper
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  1 in total

1.  The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.

Authors:  Mari S Oba; Satoshi Teramukai; Yasuo Ohashi; Kenji Ogawa; Yoshihiko Maehara; Junichi Sakamoto
Journal:  Gastric Cancer       Date:  2015-03-25       Impact factor: 7.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.